At launch we said our docking results were "in the range of approved drugs", and we pointed out a curious pattern: all three candidates had the same best-scoring target. Before moving to the lab we decided to stress-test that with control experiments.
What we did: we docked 23 unrelated molecules (steroids, triterpenoids, polyphenols, sugars, polyamines) and 7 known inhibitors into the same six pockets with identical settings, repeated the candidates with 4 random seeds, re-scored with a second scoring function, and redocked a known inhibitor into its own crystal structure.
What we found: (1) the "same best target" is an artifact of one large cavity: 22 of 26 test molecules scored best there. (2) The Vina score tracks molecule size (|r| about 0.7 to 0.94); after correcting for size none of our candidates stands out, and random steroids scored as well as our best "hit". (3) Known inhibitors are not distinguishable from size-matched random molecules in that box, and the best-known one failed to reproduce its experimental pose there (about 7.5-8 angstroms off), although it reproduced it to 0.96 angstroms in its own crystal structure. (4) Under a second scoring function the pattern mostly disappears.
So for us docking is a way to prioritize hypotheses, not evidence of binding. We have removed the "approved-drug range" wording from this launch page, our website and our chatbot. This does not mean the compounds don't work; it means docking cannot show that by itself. Independent lab assays are the decisive step, and we are arranging them now.
Hi Product Hunt! I've spent the last months building a computational pipeline that screens traditional-medicine remedies (Ayurveda, Traditional Chinese Medicine, dietary folk pharmacology) against molecular targets involved in aging, using molecular docking (AutoDock Vina). The idea: centuries of empirical trial-and-error in folk pharmacology already found candidates worth a second look — modern structural biology can help us decide which ones are worth pursuing, before spending years and real money on wet-lab work.
We're pre-seed: 3 finalist candidates out of 39, docking used only to prioritize hypotheses (our own control tests show scores alone can't prove binding), and we're now looking for a regulatory partner, a wet-lab partner for in vitro validation, and sourcing/manufacturing contacts. There's also a small Polygon-based membership token for early backers who want to pledge toward future products and lock in a discount — not an investment, just a crowdfunding-style way to back the project.
Would love feedback, especially from anyone in geroscience, drug discovery, or natural-products research. Happy to answer anything in the comments!